Drug
Mci 186
Mci 186: highest development phase Phase 3, developed by Shionogi. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| MCI-186 NCT00415519 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) |
| MCI-186 NCT00424463 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) |
| MCI-186 NCT04029090 | Phase 1 | Healthy Adult Subjects |
Latest
No recent events.
Follow Mci 186 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.